1. Home
  2. ADAP vs OFAL Comparison

ADAP vs OFAL Comparison

Compare ADAP & OFAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADAP
  • OFAL
  • Stock Information
  • Founded
  • ADAP 2008
  • OFAL 2013
  • Country
  • ADAP United Kingdom
  • OFAL United States
  • Employees
  • ADAP N/A
  • OFAL N/A
  • Industry
  • ADAP Biotechnology: Pharmaceutical Preparations
  • OFAL Military/Government/Technical
  • Sector
  • ADAP Health Care
  • OFAL Consumer Discretionary
  • Exchange
  • ADAP Nasdaq
  • OFAL Nasdaq
  • Market Cap
  • ADAP 21.3M
  • OFAL 21.4M
  • IPO Year
  • ADAP 2015
  • OFAL 2025
  • Fundamental
  • Price
  • ADAP $0.06
  • OFAL $1.58
  • Analyst Decision
  • ADAP Hold
  • OFAL
  • Analyst Count
  • ADAP 6
  • OFAL 0
  • Target Price
  • ADAP $1.02
  • OFAL N/A
  • AVG Volume (30 Days)
  • ADAP 89.0M
  • OFAL 398.8K
  • Earning Date
  • ADAP 08-13-2025
  • OFAL 01-01-0001
  • Dividend Yield
  • ADAP N/A
  • OFAL N/A
  • EPS Growth
  • ADAP N/A
  • OFAL N/A
  • EPS
  • ADAP N/A
  • OFAL N/A
  • Revenue
  • ADAP $65,084,999.00
  • OFAL $202,007.00
  • Revenue This Year
  • ADAP N/A
  • OFAL N/A
  • Revenue Next Year
  • ADAP $52.35
  • OFAL N/A
  • P/E Ratio
  • ADAP N/A
  • OFAL N/A
  • Revenue Growth
  • ADAP N/A
  • OFAL N/A
  • 52 Week Low
  • ADAP $0.05
  • OFAL $1.09
  • 52 Week High
  • ADAP $1.33
  • OFAL $9.79
  • Technical
  • Relative Strength Index (RSI)
  • ADAP 29.42
  • OFAL N/A
  • Support Level
  • ADAP $0.05
  • OFAL N/A
  • Resistance Level
  • ADAP $0.09
  • OFAL N/A
  • Average True Range (ATR)
  • ADAP 0.01
  • OFAL 0.00
  • MACD
  • ADAP 0.00
  • OFAL 0.00
  • Stochastic Oscillator
  • ADAP 7.21
  • OFAL 0.00

About ADAP Adaptimmune Therapeutics plc

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

About OFAL OFA Group Ordinary Shares

OFA Group, through its subsidiary, provides architectural services, including design and fit-out services for commercial and residential buildings in Hong Kong. The design service includes both the consultation with staff and the actual design work and the company provides a specific conceptualized design with layout plans, detailed design drawings, advice relating to, among other things, budgetary consideration, optimal use of space, the materials, fittings, furniture, appliances and other items to be used to produce a preliminary design plan and quotation. Its works include installing protective materials to cover floors or walls, installing or constructing partition walls, windows, window frames, and decorative fittings, furniture or fixtures, installing plumbing systems, etc.

Share on Social Networks: